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closely preceded the onset of autoimmunity in 28.6% of cases. Autoimmune cytopenias had early onset 167 (median 1.9, 2.1, and 2.6 years for autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP) 168 and autoimmune neutropenia (AN), respectively) and were refractory to intravenous immunoglobulin, steroids, 169
and rituximab in the majority of cases (64.7%, 73.7%, and 71.4% for AIHA, ITP, and AN, respectively). Evans 170 syndrome specifically was associated with lack of response to first-line therapy. Treatment-refractory 171 autoimmunity/hyperinflammation prompted hematopoietic stem cell transplantation in 20 patients.
172
Conclusions: Autoimmunity/hyperinflammation can be a presenting sign of RAG deficiency and should 173 prompt further evaluation. Multi-lineage cytopenias are often refractory to immunosuppressive treatment and 174 may require hematopoietic cell transplantation for definitive management. 175 176
Highlights

177
• 1) What is already known about this topic? Knowledge of autoimmunity in RAG deficiency has been 178 limited to small case series; herein we introduce the largest international database of RAG deficient 179 cases with prominent autoimmune and hyperinflammatory disease facilitating detailed outcomes and 180 treatment analysis.
181
• 2) What does this article add to our knowledge? RAG diagnosis is delayed in the setting of 182 autoimmunity or hyperinflammation (median 5 years); autoimmune cytopenias are prevalent (84.1%), 183 have early-onset (median 1.9-2.6 years), and lack of first-line treatment response correlates strongly 184 with multi-lineage disease. 185
• 3) How does this study impact current management guidelines? RAG deficiency can present with 186 autoimmunity/hyperinflammation; low naïve (CD45RA+) T cells counts are a useful diagnostic tool; 187 multi-lineage cytopenias are refractory to immunosuppressive treatment in most cases and should 188 prompt expedited hematopoietic cell transplantation evaluation. 189 190 Immune Deficiency Treatment Consortium (PIDTC) (19) . The CID-G/AI phenotype was defined by a 239 clinical history of recurrent infections and immune dysregulation (autoimmunity and/or granulomas) (6-10). 240 2. Patient database. Based on the literature search above and our data repository of unpublished cases, we 241 generated a highly annotated and curated patient database that included 63 cases. Information was 242 collected as follows: gender, age (current as of November 2017, at clinical diagnosis of immunodeficiency 243 and/or autoimmunity, at molecular diagnosis of RAG deficiency, and at death or HSCT where applicable), 244 genotype (specific RAG1 or RAG2 mutations), immune phenotype (lymphocyte counts and function, 245 immunoglobulin levels, and autoantibodies), autoimmune/hyperinflammatory complications (type, age at 246 onset, preceding infections if available, length, and severity), and therapies trialed (including response and 247 complications). Predicted V(D)J recombination activity was recorded as previously described (20, 21) . 248
Keywords
The study was approved by the Institutional Review Board of the University of South Florida (protocol # 249 Pro00025693). 250 3. Therapeutic Response Score. Therapeutic response was scored for all annotated cases of autoimmune 251 cytopenias and granulomas using the following criteria: 'no' = no clinical response to the intervention was 252 seen or side effects were limiting; 'partial' = some clinical improvement to the intervention was seen but 253 therapeutic escalation was ultimately required for stabilization; or 'full' = clinical improvement to the 254 intervention was seen and no subsequent escalation has been required for stabilization to date. Across all 255 centers, the term 'treatment-refractory' was applied only in cases where 'no clinical response to 256 intervention' was specifically documented by the managing clinical care team. 257 4. Statistical analysis. All data were assembled and analyzed using GraphPad Prism software. Groups 258 were compared using a two-tailed Student's t-test. Kaplan-Meier curves were compared using a log-rank 259 (Mantel-Cox) test. Significance was defined as P < 0.05. 260
261
Results
262
RAG deficient cases based on literature search (n=85) 263
We performed a literature search of published cases of RAG deficiency between 2001 and 2016 and 264 identified 134 cases, of which 85 met criteria for further analysis. In review of these 85 published cases, 265 autoimmune and/or hyperinflammatory complications were identified in 57 patients (67.1% of total cases) 266 ( Figure 1A) , and included autoimmune cytopenias (n=33, 57.9%), granulomas (n=9, 15.8%), skin disease 267 (n=8, 14.0%), vasculitis (n=3, 5.3%), neuropathy (n=3, 5.3%), interstitial lung disease (ILD) (n=2, 3.5%), and 268 myopathy (n=1, 1.8%) ( Figure 1B) . 269
We next compared the RAG deficient patients without vs. with autoimmune and hyperinflammatory clinical 270 manifestations. Gender and genotype were evenly distributed, and RAG1 mutations accounted for the majority 271 of patients in both groups ( Figure 1C) . In review of the clinical phenotype, 32 patients with CID-G/AI 272 accounted for the majority of the autoimmune/hyperinflammatory subset (32 out of 57 patients, 56.1%). 273
Additionally, autoimmune and/or hyperinflammatory complications were prominent among patients with AS (11 274 out of 15 patients, 73.3%), but rare among patients with Omenn syndrome (6 out 17, 35.3%) and SCID (2 out 275 of 12, 16.7%) ( Figure 1D) . Finally, no significant difference was observed in the proportion of patients who 276 received HSCT among patients without vs. with immune dysregulation, but the latter group received HSCT at a 277 significantly older age (median 0.3 vs. 6.6 years in patients without vs. with immune dysregulation, P = 0.0003) 278 ( Figure 1E ). To gain more insights into the natural history of patients with RAG deficiency complicated by 279 immune dysregulation, we created a curated longitudinal database and analyzed the data. 280 281
Annotated and curated patient database (n=63) 282
Based on the literature search and our own database of unpublished cases, we identified 63 total cases of 283 RAG deficiency with prominent autoimmune and/or hyperinflammatory manifestations. The characteristics of 284 this patient cohort are described in Table 1 Figure 2B) . Thirty-nine patients (61.9%) were alive at the time of review at a median age of 10.6 years 292 ( Figure 2C ). The median age at clinical diagnosis (immunodeficiency and/or autoimmunity) was 2.5 years. In 293 comparison, the median age of genetic diagnosis of RAG deficiency was 7.5 years, with six cases identified 294 post-mortem. In total, 45 patients (71.4%) had received HSCT at the time of review at a median of 5.0 years of 295 age. Additionally, 8 patients (12.7%) were either being evaluated for HSCT or had passed away prior to 296 anticipated HSCT at the time of review. There were no occurrences of solid organ transplantation. Twenty-297 four patients (38.1%) were deceased at the time of review at a median age of 8.4 years, which was statistically 298 coincident with the age of genetic diagnosis (P = 0.70) ( Figure 2D ). Multi-organ failure and/or sepsis was the 299 leading cause of death in ten cases (41.7%) ( Figure E1A ). Median patient survival was 14 vs. 21 years in 300 untransplanted compared to hematopoietic cell transplanted patients, however, these Kaplan-Meier curves 301 failed to reach statistical difference ( Figure E1B ; P = 0.42 Figure 3A) . Interestingly, 26.3% of patients with CID-G/AI and AS manifested hypergammaglobulinemia. 307
Increased serum IgE levels were present in the two patients with Omenn syndrome (IgE 427 and 2,448 IU/mL, 308 respectively). T and B lymphocyte counts were decreased overall in the curated patient database (medianM A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 9 CD3+ 599 cells/µL, median CD19+ 102.5 cells/µL), whereas NK cells were in the normal range (median 279.5 310 cells/µL) ( Table E1) . As expected by clinical phenotype, loss of T and B lymphocytes was most pronounced 311 for patients with SCID vs. CID-G/AI and AS ( Figure 3B ). Within the CD4+ T cell compartment, CD45RA+/RO+ 312 subtyping was available for 26 and 31 patients with CID-G/AI and AS, respectively, and demonstrated a 313 predominance of memory (CD45RO+) CD4+ T cells in circulation for both groups ( Figure 3C) . Expansion of 314
TCRγδ
+ T cells was documented in three patients with AS and in the single patient with HIM (data not shown). 315
Data on T cell proliferation to phytohemagglutinin (PHA) were available in 33 cases and were low to severely 316 low in the majority (26 patients) ( Table E1) . 317
The most frequent autoimmune and/or hyperinflammatory complications were autoimmune cytopenias 318 (n=53, 84.1%), granulomas (n=15, 23.8%), and skin manifestations including vitiligo, psoriasis, and alopecia 319 (n=12, 19.0%) (Figure 4A ). 55.6% of patients had more than one autoimmune or hyperinflammatory 320 complication, specifically 60.4% of cytopenia cases presented with an additional 321 autoimmune/hyperinflammatory manifestation ( Figure 4B) .
Infections closely preceded the onset of 322 autoimmunity in 28.6% of cases ( Figure 4C ). Viruses were the most frequent etiology in 16 cases and 323 included both live vaccinations and natural infections ( Table 1) . Infections due to Leishmania and Salmonella 324 preceded development of autoimmunity in a single patient each. The burden of treating autoimmune and 325 hyperinflammatory complications was substantial as measured by use of steroids, biological agents, and HSCT 326 ( Figure 4D ). Treatment-refractory autoimmunity and/or hyperinflammation were an indication to HSCT in 20 327 cases (44.4% of total HSCT) and included: autoimmune cytopenias (n=12), inflammatory bowel disease 328 (IBD)/enteropathy (n=4), granulomas (n=3), vasculitis (n=3), and progressive pulmonary disease (n=1). 329
Finally, type of immune dysregulation (cytopenia, granuloma, or 'other') did not correlate with the average 330 predicted level of patient recombination activity (29.9, 36.5, and 34.8% of wild-type protein, respectively) 331 ( Figure E2 ), perhaps due to the high co-occurrence of these conditions ( Figure 4B ). However, cumulative 332 number of autoimmune/hyperinflammatory complications per patient did correlate both positively and linearly 333 with the average predicted level of patient recombination activity (17.3, 36.0, and 49.6% of wild-type protein for 334 patients with one, two, or three autoimmune/hyperinflammatory complications, respectively) ( Figure 4E ). 335 336 3. Autoimmune Cytopenias: Occurrence, Outcomes, and Treatment 337
Autoimmune hemolytic anemia (AIHA) was the most frequent autoimmune complication identified in the 338 curated patient database (n=38, 60.3%), followed by immune thrombocytopenia (ITP) (n=23, 36.5%), and 339 autoimmune neutropenia (AN) (n=21, 33.3%). Evans syndrome was observed in 13 cases (20.6%), and 340 pancytopenia was observed in 8 cases (12.7%) ( Figure 5A ). The median age at onset was 1.9 years for 341 AIHA, 2.1 years for ITP, and 2.6 years for AN, which coincided with the clinical diagnosis of 342 immunodeficiency/autoimmunity, but statistically preceded the molecular diagnosis of RAG deficiency by a 343 median of 5.5 years ( Figure 5B) . Moreover, the cytopenias were often severe. The median cell nadir during 344 disease flare was hemoglobin of 5.5 g/dL for AIHA, platelet count of 20,000 cells/µL for ITP, and absolute 345 neutrophil count (ANC) of 200 cells/µL for AN ( Figure 5C ). Additionally, median duration of relapsing/remittingM A N U S C R I P T
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10 cytopenia disease course in total was 1.5 years for AIHA and 1 year for ITP and AN ( Figure 5D ). Finally, the 347 majority of patients with cytopenias had positive auto-antibodies to at least one cell lineage, including Coombs 348 (n=30, 55.6%), anti-granulocyte (n=10, 18.5%), and anti-platelet antibodies (n=5, 9.3%) ( Figure 5E 
respectively. 365
To further investigate clinical features that correlate with response to treatment for cytopenias, we 366 analyzed patients that had definitive control at first-line therapy (R-first-line) vs. patients that had definitive 367 control following rituximab (R-rituximab) vs. patients with incomplete response ('no' or 'partial') to all first-368 and/or second-line therapies trialed to date (NR). For AIHA, in comparison to R-first-line, we observed lower 369 hemoglobin nadirs in the NR (median 4.3 vs. 7.0 g/dL, P = 0.035) and the R-rituximab (median 5.0 g/dL vs. 7.0 370 g/dL, P = 0.0047). In addition, we observed more frequent occurrence of multi-lineage cytopenias in the NR 371 (median 2 vs. 1 cell lineage affected, P = 0.015). There was also a trend towards earlier age at onset of 372 cytopenias in the NR and R-rituximab that did not meet statistical significance ( Figure 6D ). For ITP and AN, 373 we had only a single patient who met criteria for R-rituximab, precluding further subset analysis. However, a 374 similar observation of multi-lineage cytopenias in the NR vs. R-first-line was seen for ITP (median 2 vs. 1 cell 375 lineage affected, P = 0.018), with a trend towards significance for AN (median 2 vs. 1 cell lineage affected, P = 376 0.097) (Figure 6E & F) . Finally, for AN we observed a later age at onset in the NR vs. R-first-line (0.75 vs. 4 377 years, P = 0.0099) ( Figure 6F ). Together these data suggest that several factors correlate with lack of 378 response to first-line therapy in autoimmune cytopenias, in particular: 1) Evans syndrome (≥ 2 affected 379 lineages); 2) low hemoglobin nadir (≤ 5.0 g/dL) in patients with AIHA; and, 3) delayed age at onset (≥ 4 years) 380 in patients developing AN. In total, 42 patients (66.7%) presented with other autoimmune or hyperinflammatory complications 384 either alternatively (15.9%) or additionally (50.7%) to cytopenias. Granulomas were the most common, 385 occurring in 15 patients (23.8%). Most granulomas were confined to a single organ (60.0%) with a subset of 386 patients who developed multi-organ disease (40.0%). Single organ granulomas were predominantly limited to 387 the skin (n=6) with the exception of two patients with lung granulomas and one patient with liver granulomas. 388
However, a variety of organs may be affected by granulomas, including skin (n=10), lungs (n=5), liver (n=3), 389 bone (n=3), oropharynx (n=2), spleen (n=2), pancreas (n=1), and testes (n=1) (Figure 7A) . Inflammatory skin 390 disorders were also prominent in the curated patient database, occurring in 12 patients (19.0%), and included 391 combinations of vitiligo (n=6), psoriasis (n=2), alopecia (n=2), eczema/dermatitis (n=2), urticaria (n=1), and 392 non-infectious nail dystrophy (n=1). Vasculitis occurred in 5 patients (7.9%), and when further annotated, was 393 complicated by digital necrosis (n=2), stroke and Henoch-Schönlein purpura (n=1), and skin manifestations 394 only (n=1). Enteropathy occurred in 5 patients (7.9%) and was annotated as IBD (n=2), autoimmune 395 enteropathy (n=1), duodenitis (n=1), and severe non-infectious diarrhea (n=1). Autoimmune neuropathy 396 occurred in 5 patients (7.9%) and was recorded as Guillain-Barré syndrome, Miller Fisher syndrome, 397 myasthenia gravis, central demyelinating neuropathy, and aseptic encephalitis in one patient each. 398
Endocrinopathies occurred in 5 patients (7.9%) and included autoimmune thyroiditis (n=4) and type I diabetes 399 mellitus (n=1). Hepatitis occurred in 4 patients (6.3%) and included autoimmune hepatitis (n=3) and sclerosing 400 cholangitis (n=1). Malignancy occurred in 3 patients (4.8%) and was exclusively lymphoma (one cutaneous T 401 cell lymphoma, one mucosa-associated lymphoid tissue (MALT) lymphoma, and one EBV-driven B cell 402 lymphoma of the tonsil). Finally, there were rare cases of inflammatory myopathy (n=2), minimal change 403 nephropathy (n=1), and uveitis (n=1). 404
Despite wide patient-to-patient variability, the median age of onset of vasculitis (1.6 years), 405 nephropathy (1.6 years), thyroiditis (1.75 years), hepatitis (2.0 years), and neuropathy (2.0 years) indicated 406 that these were among the earliest immune dysregulatory complications ( Figure 7B) . In contrast to the 407 autoimmune cytopenias, however, none of these complications statistically preceded the timing of genetic 408 diagnosis, suggesting lower yield benefit in terms of facilitating the diagnosis of RAG deficiency. Autoantibody 409 production was prominent, with anti-nuclear (ANA), anti-cytokine, and anti-thyroid antibodies being most 410 common ( Figure 7C) . 411
Treatment outcomes were well annotated in 10 of the 15 patients who developed granulomas (Figure  412 7D). Spontaneous granuloma resolution was seen in two patients with skin manifestations only, while the 413 remainder of patients (80.0%) did not respond to first-line IVIG and/or steroids. Of the second-line agent 414 trialed, only infliximab resulted in full response in one patient with multi-organ disease as well as partial 415 response (temporizing for years) in one patient with isolated lung granulomas. Ultimately, HSCT was required 416 for definitive management in 5 cases (50.0%) without granuloma recurrence to date.
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Among the five patients with vasculitis, topical and systemic steroids were sufficient to induce remission 418 in one case of late-onset (8 years) disease limited to skin manifestations. In contrast first-and second-line 419 treatment with steroids, IVIG, cyclophosphamide, alemtuzumab, and/or rituximab failed to achieve a sustained 420 response in the remaining four cases of early-onset (median 1.0 years) and severe disease (complicated by 421 digital necrosis, stroke, and Henoch-Schönlein purpura). Ultimately, three of these patients were stabilized 422 with HSCT while the final patient passed away prior to anticipated HSCT. 423
Three of the five cases of enteropathy had well annotated treatment outcomes. There was limited 424 response to first-and/or second-line therapy with steroids, non-steroidal anti-inflammatories, cyclosporine, and 425 sirolimus in all three cases. Adalimumab (Humira) was temporizing for a year in one case of duodenitis, 426 however, all three cases ultimately required progression to transplant for definitive management. Cytopenias were the most frequent autoimmune/hyperinflammatory manifestation in our series and 461 presented early in life (median onset 1.9 years for AIHA, 2.1 years for ITP, and 2.6 years for AN). A lack of 462 response to first-line therapy (predominantly IVIG and steroids) and second-line therapy (predominantly 463 rituximab) was observed in the majority of cases. In particular, complete remission after use of rituximab was 464 achieved in only 28.9% of AIHA cases, 16.7% of ITP cases, and 20.0% of AN cases. These data are in 465 contrast to the benefit of rituximab that has been reported in the literature previously in CVID patients with 466 autoimmune cytopenias (85% initial complete patient response rate for AIHA and/or ITP) (25), and more 467 closely resemble the intermittent rituximab responsiveness for autoimmune cytopenias reported previously in 468 patients with combined T cell dysfunction syndromes, including autoimmune lymphoproliferative syndrome 469 (ALPS) ( Table E2 ). However, we acknowledge the limitation of our retrospective, international, multicenter 470 study, which relied on physician annotation to score therapeutic response as compared to the more objective 471 measure of cell counts used in CVID previously (25). In our case series, multi-lineage cytopenias, a low nadir 472 of hemoglobin (≤ 5.0 g/dL) during AIHA episodes, and later age of onset (≥ 4 years) for AN were associated 473 with lack of response to first-line treatment of autoimmune cytopenias. Sirolimus has been shown to be 474 beneficial in the management of refractory cytopenias in patients with ALPS and CVID (26); however, it was 475 used in only two patients in the present case series, and additional experience must be collected to document 476 its efficacy in RAG deficiency. Definitive therapy with HSCT was successful in the majority of RAG deficient 477 patients with severe autoimmune cytopenias in this series. Thus, while RAG deficiency is a small contributor 478 to the overall incidence of autoimmune cytopenias in the general population, these data suggest that 479 consideration of RAG deficiency in the differential diagnosis of treatment-refractory multi-lineage disease 480 specifically may have potential therapeutic benefit, specifically early consideration of HSCT for definitive 481
management. 482
Granulomas were the second most prevalent autoimmune/hyperinflammatory complication identified 483 (23.8%) in this series. Single organ disease was more frequent and often limited to the skin. TNF inhibitors 484 were used in three patients in this series and led to full remission in one patient with multi-organ disease and 485 partial and transient response in another patient with lung granulomas. Additional clinical experience must be 486 collected to evaluate the efficacy of this treatment. On the other hand, 50% of the patients with treatment-487 refractory granulomas ultimately required HSCT for definitive management in this series.
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Finally, vasculitis occurred early in the course of RAG deficiency (median 1.6 years), was often 489 complicated by significant end-organ involvement, and in most cases was not responsive to first-or second-490 line therapy but required HSCT for definitive management in this series. Similarly, the majority of patients with 491 severe gastrointestinal manifestations required HSCT for definitive management in this series. One patient 492 experienced initial benefit from adalimumab. 493
Overall, our data demonstrate that immune dysregulation is a common feature of RAG deficiency and is 494 often refractory to conventional medical management. Characterization of factors associated with lack of 495 response to first-and second-line treatment may help to identify patients in which HSCT should be considered 496 early in the course of the disease, before development of severe organ damage. 497 
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